Either a period of relative stability for Lloyds Banking Group (LLOY), or uncertainty over the outlook for the UK mortgage market, seems to have given some of its directors the confidence (or the frit, as Margaret Thatcher might have said) to sell sizeable bundles of shares in recent days, clearly as the post-results lock-in period expired.
First up is the head of Scottish Widows, and group director of insurance, pensions and investments, Antonio Lorenzo. Lorenzo, who originally joined Lloyds from Santander, sold about £1.2mn-worth of shares – approximately 2.75mn at 44.8p a share. Whether these were vesting options or personal holdings is not clear. Lorenzo runs the now strategically important wealth management division for Lloyds, which the bank is relying on as it tries to diversify its business revenues away from the UK mortgage market. As such, he has had a busy year as Lloyds ramps up its wealth management operations.
He was joined in the summer sale by Lloyds’ interim chief operating officer David Oldfield, a company lifer who began his career with the bank in 1984. As well the interim role, he currently oversees the bank’s commercial lending arm. Oldfield sold a more modest £500,000-worth of shares.
On balance, it is probably worth considering the general prospects for Lloyd’s before jumping to any conclusions. The last set of results showed that the bank is clearly floating on an upward trend when it comes to interest rates, with net interest margins only set to widen given how aggressively the Bank of England is now signalling its inflation-fighting intentions. With such a mature and dominant business, there is no sign that the shares will move quickly in either direction, so locking profits from vesting options has a certain logic.
Buys | |||||
Company | Director/PDMR | Date | Price (p) | Aggregate value (£) | Stake size |
Airtel Africa | John Danilovich | 28 Jul 22 | 159 | 97,000 | n/d |
Alfa Financial | Christopher Sullivan | 29 Jul 22 | 149 | 238,196 | n/d |
Arecor Therapeutics | Christine Soden ** | 04 Aug 22 | 300 | 20,001 | 0.10% |
Arecor Therapeutics | Sam Fazeli ** | 04 Aug 22 | 300 | 23,268 | 0.40% |
BP | Tushar Morzaria | 02 Aug 22 | 406 | 81,249 | n/d |
Bridgepoint | Raoul Hughes (PDMR) | 02-03 Aug 22 | 251 | 502,184 | 0.01% |
British American Tobacco | Karen Guerra | 03 Aug 22 | 3,264 | 97,911 | n/d |
Card Factory | Kristian Lee (cfo) | 01 Aug 22 | 54 | 42,000 | 0.05% |
Conduit | Trevor Carvey (ce) | 28 Jul 22 | 355 | 76,600 | 0.16% |
Foxtons | Nigel Rich (ch) | 02 Aug 22 | 42 | 63,300 | n/d |
Greggs | Matthew Davies (ch-d) | 02 Aug 22 | 2,126 | 42,518 | n/d |
GSK | Diana Conrad (PDMR) | 27 Jul 22 | 3,571 † | 189,277 † | n/d |
Haleon | Bryan Supran | 01 Aug 22 | 601 | 150,331 | n/d |
Haleon | John Young | 02 Aug 22 | 312 | 251,288 | n/d |
Haleon | Vindi Banga | 01 Aug 22 | 291 | 285,180 | n/d |
Hill & Smith | Alan Giddins (ch) | 03 Aug 22 | 1,166 | 49,555 | 0.03% |
Integrated Diagnostics | Dr Hend El Sherbini (ce) * | 29 Jul-03 Aug 22 | 74 † | 2,874,246 † | n/d |
Intertek | Graham Allan | 01 Aug 22 | 4,243 | 84,860 | 0.00% |
Jupiter Fund Management | David Cruickshank | 01 Aug 22 | 132 | 39,600 | n/d |
Kerry Group | Christopher Rogers | 29 Jul 22 | 8,646 † | 86,456 † | n/d |
LSL Property Services | David Stewart (ce) | 04 Aug 22 | 317 | 24,750 | 0.02% |
ProCook | Daniel O'Neill (ce) | 29 Jul 22 | 35 | 175,000 | 35.10% |
Purplebricks | Paul Pindar (ch) | 02 Aug 22 | 15 | 369,000 | 4.59% |
Rio Tinto | Dominic Barton (ch) | 29 Jul 22 | 5,634 † | 371,817 † | n/d |
Robert Walters | Matt Ashley * | 03 Aug 22 | 517 | 49,978 | 0.01% |
Rolls-Royce | Anita Frew (ch) | 04 Aug 22 | 82 | 81,895 | n/d |
S4 Capital | Scott Spirit (PDMR) | 02 Aug 22 | 131 | 44,380 | 0.06% |
Sabien Technology | Richard Parris (ch) ** | 03 Aug 22 | 10 | 115,000 | n/d |
SDX Energy | Mark Reid (ce) | 02 Aug 22 | 10 | 20,345 | 0.44% |
Seraphine | Sharon Flood (ch) | 02 Aug 22 | 29 | 33,500 | 0.47% |
Seraphine | David Williams (ce) | 02 Aug 22 | 29 | 244,375 | 5.30% |
Synthomer | Roberto Gualdoni | 02 Aug 22 | 214 | 42,800 | n/d |
Synthomer | Michael Willome (ce) | 04 Aug 22 | 189 | 132,476 | n/d |
Synthomer | Alexander Catto | 03 Aug 22 | 201 | 100,376 | n/d |
Taylor Wimpey | Mark Castle | 04 Aug 22 | 125 | 49,999 | n/d |
Vianet | Stella Panu | 01 Aug 22 | 67 | 20,100 | 0.10% |
XP Power | Jamie Pike * | 01-02 Aug 22 | 2,584 | 99,192 | 0.00% |
Sells | |||||
Company | Director/PDMR | Date | Price (p) | Aggregate value (£) | Stake size |
Darktrace | Nicole Eagan PDMR) | 04 Aug 22 | 399 | 999,997 | n/d |
Lloyds | Antonio Lorenzo (PDMR) | 28 Jul 22 | 45 | 1,232,000 | n/d |
Lloyds | David Oldfield (coo) | 29 Jul 22 | 45 | 494,978 | n/d |
Redx Pharma | Dr. Richard Armer (PDMR) ** | 05 Aug 22 | 59 | 295,000 | 1.82% |
Softline | Igor Borovikov (ch) | 01 Apr 22 | 171 † | 48,788 † | n/d |
Stanley Gibbons | Harry Wilson (ch) | 04 Aug 22 | 2 | 30,000 | 0,00% |
*Spouse/Family/Close Associate. ** placing / open offer † Converted from € / $ / AUS$ |